Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of droxidopa in neurogenic orthostatic hypotension
2008-007105-36Phase 3Terminated
- Sponsor
- Chelsea Therapeutics International, Ltd.
- Start
- Apr 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of droxidopa in Neurogenic Orthostatic Hypotension (nOH), sponsored by Chelsea Therapeutics International, Ltd. Primary endpoint: Long-term safety. Started Apr 2009; status: terminated.
02
Drugs
droxidopa
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on 2008-007105-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007105-36.